New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 10, 2013
07:04 EDTCCXIChemoCentryx says interim data support continued dosing in Phase II study
ChemoCentryx announced interim data from an ongoing Phase II study in patients with diabetic nephropathy, also known as diabetic kidney disease, with CCX140. CCX140 is an inhibitor of the chemokine receptor known as CCR2, and the drug candidate is wholly owned by the company. Examining data through the first 12 weeks of dosing in the ongoing 52 week trial, in which CCX140 is added on top of the standard of care for diabetic nephropathy patients, the drug candidate appears well-tolerated in the patient population to date. The safety observations were consistent with a concurrent analysis by the company's independent safety data monitoring committee, which independently assessed the interim data and recommended no changes to the ongoing study protocol. In addition, data also showed that patients treated with 5 mg CCX140 once daily experienced a statistically significant reduction of protein in the urine, or proteinuria, as measured by Urinary Albumin Creatinine Ratio versus those patients receiving only the standard of care, following two weeks of treatment, with continuing downward trends in UACR observed following 8-weeks and 12-weeks of treatment with CCX140. In pre-specified analyses of subsets of patients in the study, greater reductions in proteinuria were observed, including decreases of approximately 30% in UACR in the CCX140 groups versus those patients only on background medications. The company indicated that the data support the continued progress of full 52 weeks of dosing in the Phase II trial as planned. Data from the full study are expected in the second half of 2014, which will continue to monitor proteinuria as well as assess additional markers related to kidney function, including serum creatinine and estimated glomerular filtration rate, measures which historically take longer to be detected in clinical trials.
News For CCXI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
16:31 EDTCCXIChemoCentryx grated FDA orphan-drug designation for CCX168
Subscribe for More Information
November 18, 2014
16:07 EDTCCXIChemoCentryx atypical hemolytic uremic syndrome treatment granted orphan status
Subscribe for More Information
November 17, 2014
08:52 EDTCCXIChemoCentryx reported additional data from CCX168 Phase II clinical trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use